MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Начало・Списък с акции・Dynavax Technologies Corp

Dynavax Technologies Corp

Затворен

СекторЗдравеопазване

10.05 1.11

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

9.73

Максимум

10.37

Ключови измерители
By Trading Economics
Приходи	-103M -96M
Продажби	-3.9M 68M
P/E Средно за сектора	58.75 40.527
Марж на печалбата	-140.982
Служители	405
EBITDA	-106M -94M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+121.77% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-477M 1.2B
Предишно отваряне	8.94
Предишно затваряне	10.05

Настроения в новините

By Acuity

49%

51%

161 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.62 / 10.9 Подкрепа & съпротива

Dynavax Technologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.07.2025 г., 23:09 ч. UTC

Печалби

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1.07.2025 г., 19:16 ч. UTC

Придобивния, сливания и поглъщания

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1.07.2025 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1.07.2025 г., 23:41 ч. UTC

Пазарно говорене

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1.07.2025 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

James Hardie: Deal Represents Implied Value of $8.4 Billion

1.07.2025 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1.07.2025 г., 22:21 ч. UTC

Придобивния, сливания и поглъщания

James Hardie Completes Acquisition of AZEK

1.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

1.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

1.07.2025 г., 20:24 ч. UTC

Печалби

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1.07.2025 г., 19:55 ч. UTC

Пазарно говорене

Oil Futures Resume Cautious Rally -- Market Talk

1.07.2025 г., 19:27 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1.07.2025 г., 19:12 ч. UTC

Пазарно говорене

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1.07.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1.07.2025 г., 18:41 ч. UTC

Придобивния, сливания и поглъщания

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1.07.2025 г., 18:33 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

1.07.2025 г., 18:33 ч. UTC

Пазарно говорене

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1.07.2025 г., 18:32 ч. UTC

Пазарно говорене

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1.07.2025 г., 18:22 ч. UTC

Пазарно говорене

Remittances to Mexico Down in May -- Market Talk

1.07.2025 г., 17:45 ч. UTC

Пазарно говорене

Seasonal Demand Supports Further Oil Gains -- Market Talk

1.07.2025 г., 17:01 ч. UTC

Придобивния, сливания и поглъщания

Danone Completed Acquisition of Majority Stake in Kate Farms

1.07.2025 г., 16:55 ч. UTC

Печалби

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1.07.2025 г., 16:27 ч. UTC

Пазарно говорене

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1.07.2025 г., 16:25 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

1.07.2025 г., 15:48 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1.07.2025 г., 15:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

1.07.2025 г., 15:46 ч. UTC

Пазарно говорене

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1.07.2025 г., 14:54 ч. UTC

Пазарно говорене

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1.07.2025 г., 14:49 ч. UTC

Пазарно говорене

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Dynavax Technologies Corp Прогноза

Ценова цел

By TipRanks

121.77% нагоре

12-месечна прогноза

Среден 22 USD 121.77%

Висок 31 USD

Нисък 10 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Dynavax Technologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Dynavax Technologies Corp през последните 3 месеца.

Техническа оценка

By Trading Central

9.62 / 10.9Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

161 / 380 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Dynavax Technologies Corp

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.